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Ciprofloxacin-
resistant
Salmonella
Kentucky in
Travelers
To the Editor: Ciprofloxacin is
the treatment of choice of severe non-
typhoidal  Salmonella infections in
adults. Resistance to ciprofloxacin has
been found exceptionally in nonty-
phoidal  Salmonella enterica isolates
and only in serotypes Typhimurium,
Choleraesuis, and Schwarzengrund
(1–8). Such isolates have been col-
lected from humans and animals in
Europe, Asia, and North America.
We report the emergence of
ciprofloxacin-resistant isolates of S.
Kentucky since 2002 in French travel-
ers returning from northeast and east-
ern Africa. From 2000 through 2005,
197  S.  Kentucky isolates from
humans (1 per patient) were
serotyped, from 69,759 total S. enter-
ica isolates serotyped at the French
National Reference Centre for
Salmonella. Antimicrobial drug sus-
ceptibility was determined for 186
isolates by the disk-diffusion method
with 32 antimicrobial drugs, as previ-
ously described (9). Resistance to sev-
eral drugs, amoxicillin (18%), gen-
tamicin (16%), nalidixic acid (21%),
sulfonamides (24%), and tetracycline
(24%), has been observed from 2000
through 2005.
A total of 17 (9%) ciprofloxacin-
resistant S. Kentucky strains were iso-
lated. Aresistant isolate that was unty-
pable by conventional serotyping
(rough) but that had a pulsed-field gel
electrophoresis (PFGE) profile asso-
ciated with serotype Kentucky, was
included in this study. Ciprofloxacin
MIC levels in these isolates, deter-
mined by standard agar doubling dilu-
tion as previously described (2), were
4–16 mg/L. The first ciprofloxacin-
resistant strain was isolated in
December 2002 from a French tourist
who had gastroenteritis during a Nile
cruise in Egypt. In 2004 and 2005, 17
ciprofloxacin-resistant isolates were
identified in unrelated adults who
lived in different cities of France at
different times of the year. The 16
patients we contacted acquired the
infection during or immediately after
travel to Egypt (10 patients), Kenya
and Tanzania (3), or Sudan (1). In 2
cases, gastroenteritis occurred 2
months after travel to Egypt. None of
the investigated cases were fatal or
life-threatening.
The 18 ciprofloxacin-resistant iso-
lates (17 serotype Kentucky and 1
rough) displayed various susceptibili-
ty patterns, from single resistance to
quinolones to multiple resistance (up
to 9 antimicrobial agents). To identify
mutations responsible for cipro-
floxacin resistance, the quinolone
resistance–determining regions
(QRDRs) of gyrA,  gyrB,  parC, and
parE were amplified by PCR and
sequenced as described previously
(3,9), except that different forward
primers for gyrB (5′-TTATCGACGC-
CGCGCGTGCGC-3′) and parE (5′-
CGCGTAACTGCATCG-GGTTC-3′)
were used. The 18 ciprofloxacin-
resistant isolates had different double
mutations in gyrA leading to amino
acid substitutions, Ser83Phe and
Asp87Gly (8 isolates), Ser83Phe and
Asp87Asn (5), and Ser83Phe and
Asp87Tyr (5), but had identical muta-
tions in parC (resulting in Ser80Ile).
An additional substitution was
observed in ParC, Thr57Ser. This sub-
stitution, however, did not appear to
be associated with quinolone resist-
ance because it was also identified in
nalidixic acid–susceptible isolates.
No isolates had substitutions in the
QRDRs of GyrB and ParE. All iso-
lates tested by PCR for the plasmid-
mediated quinolone resistance–con-
ferring gene qnrA (9) were negative.
In the presence of the efflux pump
inhibitor Phe-Arg-β-naphthylamide,
the MICs of ciprofloxacin were
reduced from 4-fold to 16-fold, which
suggests that an active efflux mecha-
nism was present (2). The involve-
ment of the AcrAB-TolC efflux sys-
tem was determined by measuring
AcrAexpression with a method previ-
ously described (5). A moderate pro-
duction of AcrA (3- to 4-fold increase
when compared with the baseline pro-
duction of AcrA in reference strain
98K) was observed in all but 1
ciprofloxacin-resistant isolate. This
isolate overproduced (6-fold) AcrA,
which correlated with a higher
ciprofloxacin MIC (16 mg/L).
The 18 ciprofloxacin-resistant iso-
lates and 14 ciprofloxacin-susceptible
S. Kentucky isolates used for compar-
ison were genotyped by PFGE with
XbaI restriction and PulseNet’s run-
ning conditions, as described previ-
ously (9). Each profile that differed by
>1 clear band >50 kb was considered a
distinct profile. The 18 resistant iso-
lates displayed 9 profiles that differed
by 1 to 3 bands (Dice correlation coef-
ficient 55%) (Figure). Profile X1c was
predominant (7 [39%] of 18). The 6
pansusceptible isolates tested dis-
played 5 different patterns unrelated to
those of resistant isolates. Use of aLETTERS
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second restriction enzyme, SpeI, for
the resistant isolates of X1 cluster
enhanced discrimination. No clear
correlations between combined PFGE
patterns, gyrA mutations, and probable
country of infection were observed.
Since S. Kentucky is infrequently
isolated from human, animal, or envi-
ronmental sources in France, these
isolates must have been acquired
abroad. Unfortunately, no investiga-
tions have been thus far conducted to
identify the source of the contamina-
tion in probable countries of infection.
Poultry products may be of particular
interest because poultry is the main
animal reservoir of S.  Kentucky.
Another possible source in East
Africa is pork because a recent report
identified quinolone-resistant (cipro-
floxacin MIC >0.125 mg/L) S.
Kentucky isolates in slaughtered pigs
in Ethiopia (10). After identifying the
source of the contamination, appropri-
ate control measures should be imple-
mented in the affected countries to
control the spread of these isolates.
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Figure. Dendrogram generated by BioNumerics version 4.1
(Applied Maths, Sint-Martens-Latem, Belgium) showing the
results of cluster analysis on the basis of XbaI pulsed-field
gel electrophoresis (PFGE) of Salmonella enterica serotype
Kentucky isolates. Similarity analysis was performed by
using the Dice coefficient, and clustering was performed by
the unweighted pair-group method with arithmetic means
with an optimization parameter of 0.5% and a 0.5% band
position tolerance. The different PFGE profiles, the pheno-
types of resistance to quinolones (R-type), and correspon-
ding number of isolates are indicated. CIP, ciprofloxacin;
NAL, nalidixic acid.